Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections…
Med Lett Drugs Ther. 2023 Sep 4; 65(1684):137-44 doi:10.58347/tml.2023.1684a
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders , 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol…
Med Lett Drugs Ther. 2021 Dec 13; 63(1639):193-8
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders , 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne…
Med Lett Drugs Ther. 2017 Jun 5; 59(1522):89-96
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the CDC, there were 33,091 deaths related to opioid overdose in the US in 2015, more than in any previous year. Several guidelines on the management of opioid use disorder have recently been published.
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza , has now also been approved at a higher dose as Saxenda…
Med Lett Drugs Ther. 2015 Jun 22; 57(1471):89-90
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza , has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
The FDA has approved a fixed-dose combination of the opioid receptor antagonist naltrexone ( ReVia , and others) and the antidepressant and smoking cessation agent bupropion ( Wellbutrin SR , Zyban , and…
Med Lett Drugs Ther. 2014 Nov 10; 56(1455):112-4
The FDA has approved a fixed-dose combination of the opioid receptor antagonist naltrexone ( ReVia , and others) and the antidepressant and smoking cessation agent bupropion ( Wellbutrin SR , Zyban , and others), as Contrave (Orexigen/Takeda) for weight loss. The combination was approved for use as an adjunct to diet and increased physical activity in patients with a body mass index (BMI) ≥30 kg/m 2 or a BMI ≥27 kg/m 2 and one or more weight-related comorbidities such as hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled substance.
The FDA has approved an agonist/antagonist combination of morphine and naltrexone ( Embeda – King) for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended period…
Med Lett Drugs Ther. 2010 Mar 22; 52(1334):22-3
The FDA has approved an agonist/antagonist combination of morphine and naltrexone ( Embeda – King) for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended period of time. The addition of naltrexone is intended to prevent abuse of morphine.
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone ( Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to…
Med Lett Drugs Ther. 2006 Jul 31; 48(1240):62-4
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone ( Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to maintain abstinence from alcohol. Naltrexone inhibits the rewarding effects of alcohol. Oral naltrexone ( Revia , and others) has been approved for treatment of alcohol dependence since 1994, but poor adherence has limited its effectiveness. In the new extended-release (XR) formulation, naltrexone is encapsulated in polylactide-co-glycolide microspheres (similar to absorbable suture material) and placed in aqueous suspension for intramuscular (IM) injection.
Acamprosate calcium ( Campral - Forest) is now being marketed for oral use to maintain abstinence from alcohol. It has been used in France and other countries since 1989.
Med Lett Drugs Ther. 2005 Jan 3; 47(1199):1-3
Acamprosate calcium ( Campral - Forest) is now being marketed for oral use to maintain abstinence from alcohol. It has been used in France and other countries since 1989.
Naltrexone ( ReVia -DuPont Pharma), a long-acting oral opioid antagonist previously marketed for treatment of opioid dependence under the trade name Trexan , was recently approved by the US Food and Drug…
Med Lett Drugs Ther. 1995 Jul 21; 37(953):64-6
Naltrexone ( ReVia -DuPont Pharma), a long-acting oral opioid antagonist previously marketed for treatment of opioid dependence under the trade name Trexan , was recently approved by the US Food and Drug Administration (FDA) for treatment of alcohol dependence. The new trade name will now also be used for the old indication.